“First patient in treatment for RhoVac’s clinical phase II study in Finland”

Here's some data from the prior trial: https://www.rhovac.com/cision/46DAAF83E44458D3/ https://www.prnewswire.com/news-releases/rhovac-reports-interim-results-on-immunological-response-with-rv001-300959779.html And the approval for trial initiation in Finland: https://www.rhovac.com/cision/1426FA569CA49E44/ in the U.S.: https://www.rhovac.com/cision/8163CA7465CF755B/ and in Germany and Belgium: https://www.rhovac.com/cision/DE83AF97940EEE93/
Subscribe or to access all post and page content.